Brookline starts Forte Biosciences at buy; PT $90

Brookline Capital Markets launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $90 price target. The stock closed at $26.69 on Aug. 27.

Forte Biosciences is developing FB-401, a topical live biotherapeutic for treating atopic dermatitis, or eczema. FB-401 is a combination of three strains of gram-negative bacteria, Roseomonas mucosa

Analyst Kumaraguru Raja writes that FB-401 leads to disease modifying effects in atopic dermatitis as it drives tissue repair and reduces inflammation by targeting the anti-inflammatory pathways. 

“In our view, FB-401 is expected to have a differentiated product profile, compared with corticosteroids, PDE-4 inhibitors, and immunomodulators, with high efficacy and comparatively better side effect profile,” he said. 

FB-401 is in a Phase 2 trial with patient enrollment expected near term and data expected in mid-2021. 

“We foresee a favorable risk-reward as FB-401 advances through the clinic as there is significant unmet need for convenient, topical, less frequent dosing, long acting, non-steroid based therapeutics for dermatological diseases,” Mr. Raja said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.